Clinical Trial Update: Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide plus rituximab in patients with recurrent or refractory multiple myeloma; the study was terminated with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2015-11-20